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Curing Impotence 
Once thought to be "all i n the head," 
impotence is now considered a 
physioiogicai problem affecting 10 to 
20 m i l l i o n American men. The good 
news: i t can be cured. 
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Innovative new surgical techniques, 
combined w i t h the aggressive 
management of couples and ongoing 
research, now gives some infert i le 
m e n a better chance at fatherhood. 
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A Better Lifestyle 
The development of a new drug that 
helps control nausea associated w i t h 
chemotherapy makes harsh cancer 
treatments more gentle and greatly 
improves the patient's qual i ty of l i fe . 
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The Stone Center 
Lasers and shock waves are among 
several new methods for treating 
kidney stones and gallstones at the 
Univers i ty Hospital Stone Center. 
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Straight TalkA^outStmvnts— 
Are anahoiic steroids w o r t h the risk? 
Many amateur and professional ath-
letes, and an estimated half a m i l l i o n 
high school athletes, t h i n k so. I n a 
candid interview. Dr. Robert Leach, 
top physician to the 1988 U.S. Sum-
mer O l y m p i c Team, shares his 
opinions about these drugs. 
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Exciting Possihilities 
A n excit ing new f o r m of l ight-
induced blood therapy—called 
photopheresis—has been effective i n 
treating a rare f o r m of leukemia, and 
i t holds great promise for treating 
other diseases too. 
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Easing The Transition 
A new Short Stay U n i t makes am-
bulatory patients' transitions i n t o 
and out of the Hospital smoother and 
more comfortable. 
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Answers to some c o m m o n l y asked 
health questions. 
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N e w appointments at the 
Hospital . . . 1989 Black 
Achievers. . .New M R I U n i t 
unveiled. . .SkyLight D i n i n g Pavil ion 
opens. . .UH staff i n the news. 
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CURING IMPOTENCE 
This rarely acknowledged condition, 
which affects millions of men, can he reversed 
B Y M I C H A E L R. PASKAVITZ 
M t has been the subject of 
U countless "locker room" 
U jokes. I t has caused em-
harassment and frustra-
Nm t i o n for its v ic t ims and 
their partners. I t has ended or 
threatened otherwise healthy mar-
riages or relationships. A n d i t un-
doubtedly inf l icts great damage 
upon a man's self-esteem. 
For al l the serious problems i t 
creates, impotence is not a subject 
that is easily talked about by 
many of the estimated 10 to 20 
m i l l i o n impotent American men. 
A t the N e w England Male 
Reproductive Center of the 
Univers i ty Hospital , innovative 
ways to help relieve impotence— 
ranging f r o m drug-injection 
therapy to vascular reconstructive 
surgery—offer many men new 
hope for regained potency. 
As recently as 10 years ago, i m -
potence was thought to be 90 per-
cent psychological—that is, "it's 
a l l i n your head." But research 
conducted internationally and at 
U H has proven otherwise. I t is 
now believed that as many as 80 
to 90 percent of impotency eases 
are associated w i t h physiological 
factors, the major i ty of w h i c h are 
circulatory and are treatable. 
" In general terms, an erection is 
the result of an integrated reaction 
between nerves, arteries and 
veins," says Robert J. Krane, M . D . , 
chief of the U H Department of 
Urology. "If someone is impotent , 
i t is most often because of a 
problem w i t h either the nerves, 
arteries or veins, or perhaps a com-
bination." 
The Reproductive Center, 
founded i n 1979 hy Krane and his 
then-colleague Ralph DeVere 
White , M . D . , to study impotence 
and male in fer t i l i ty , has heen a 
w o r l d leader i n the diagnosis and 
treatment of impotence. 
What causes impotence 
A man's sexual arousal begins 
w i t h the s t imula t ion of nerves. 
The nerves cause a chemical reac-
t i o n that i n t u r n activates the cor-
pora cavernosa (CC)—two rods of 
spongy erectile tissue that r u n 
along the length of the penis—to 
relax and draw i n blood f rom the 
penile artery. This blood then ex-
pands the erectile tissue and pres-
ses close the veins that normal ly 
drain blood f rom the penis, thus 
trapping the blood i n the penis to 
cause an erection. 
For this process to happen suc-
cessfully, however, the penis must 
have healthy nerves and arteries, 
and a healthy smooth muscle. "If 
the nerves don't relax the smooth 
muscle," says Krane, "if the artery 
becomes clogged and restricts 
blood f low, or if the erectile tissue 
loses its elasticity and can't al low 
for adequate expansion to close off 
the veins, impotency w i l l result." 
"As we now understand the dis-
ease," adds U H urologist I r w i n 
Goldstein, M . D . , "the penile 
arteries and erectile tissue are ex-
posed to the same vascular risk fac-
tors as the arteries and tissue i n 
the heart—high blood pressure, 
atherosclerosis, diabetes, smoking 
and trauma. A n d we have found a 
combination of restricted blood 
f low to the penis and an inabi l i ty 
to effectively trap blood w i t h i n the 
penis i n nearly 75 percent of our 
impotence cases." 
These types of damage can 
occur i n several ways. Younger 
men who are impotent i n many 
cases have lost their potency 
through traumatic damage to the 
genital area. Some have pelvic frac-
tures f rom serious accidents, such 
as an automobile crash. Some 
men have even sustained such 
damage during sexual intercourse. 
But most incurred this damage 
through sports or straddle injuries. 
• FOR YOUR INFORMATION 
Dr. Krane is 
chief of the U H »= 
Department of 
Urology, ^ 
eo-direetor of 
the Male 
Reproductive Center, and 
professor and chairman of the 
Department of Urology at Boston 
Univers i ty School of Medicine. 
D r . Goldstein, a 
member of the 
Department of 
Urology, is 
coordinator of 
the Male 
Reproductive Center, and is an 
associate professor of urology at 
the School of Medicine. 
If you w o u l d l ike more infor-
m a t i o n on treatments for i m -
potence, or on the Male 
Reproductive Center or urology 
services at the Univers i ty 
Hospital , please call 1-800-842-
3648. 
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Jllross section through 
^''corpus cavernosum 
Corpus Cavernosum 
The first phase of surgery (above left) involves "bypassing" a blocked penile artery to allow blood to flow into tbe penis. In 75 percent of 
cases, a second pbase (above rigbt), is used to prevent tbe leakage of blood from tbe penis tbrongb tbe veins. 
When these injuries occur, the 
l i n i n g of the penile arteries can be-
come damaged and the arteries 
then become vulnerable to 
atherosclerosis—the same blood 
vessel disorder that afflicts people 
w i t h heart disease. After the i n -
jury occurs, a diet h igh i n fat and 
cholesterol w i l l cause plaque to 
form i n the penile arteries, and i t 
becomes d i f f i cu l t for enough blood 
to reach the penis and cause an 
erection. 
As i n the case of heart disease, 
this blood vessel disorder happens 
over t ime . I n fact, i t may not even 
lead to impotence u n t i l several 
years after the in jury has occurred. 
"We have seen patients w h o some-
times have to t h i n k hack many 
years to rememher that they had 
an in jury that prohahly caused the 
damage," Goldstein says. 
"It also is important to point out 
that w h i l e nearly three-quarters of 
our patients have penile artery 
atherosclerosis, many also have a 
simultaneous leakage of hlood 
f r o m the penis hecause their erec-
t i le tissue has lost its elasticity; so 
impotence is not just an arterial or 
in f low problem," he notes. 
I t is believed that leakages i n 
younger patients originate f r o m the 
i n i t i a l traumatic injury, w h i c h 
prohahly results i n scarring of the 
erectile tissue. The scarring can 
cause excessive draining of blood 
through the veins hecause the erec-
t i le tissue restricts expansion to 
close off the veins, w h i c h w i l l i n -
h i b i t erections. 
Most impotent men, however, 
are over the age of 55 and their 
problem often results f r o m the ef-
fects of unhealthy lifestyle habits. 
For instance, heavy smoking con-
stricts hlood vessels and reduces 
the elasticity of the erectile tissue, 
and alcoholism can deaden nerves. 
"Research has shown that 
cigarettes and other tobacco 
products can not only affect the 
arteries leading to the penis, hut 
they also seem to increase venous 
leakage," adds Krane. 
I n addition, chronic illnesses, 
such as diabetes (50 percent of 
diabetic men are impotent) , 
atherosclerosis and high hlood pres-
sure, and their medications, also 
can contribute to impotence. 
N o t too many years ago, an i m -
potent man w o u l d have quiet ly 
been advised to seek the help of a 
psychiatrist or sex therapist to cor-
rect his problem. U n t i l around 
1980, penile implants—prosthetic 
devices that are implanted i n the 
penis to m i m i c an erection—were 
the only answer physicians had for 
impotent men. 
However, the prospects for res-
tored potency improved dramatical-
ly for many men when physicians 
at the Univers i ty Hospital and 
other medical centers hegan to 
develop new treatments. 
Before any treatment can he 
tried, however, physicians must 
k n o w where the damage is. N e w 
and sophisticated diagnostic proce-
dures help locate the cause: 
• a penile Doppler to measure 
hlood f low; 
• a hiothesiometer to record 
penile sensation, and a dorsal nerve 
somatosensory study to diagnose a 
problem of the sensation nerve of 
the penis and the central nervoiis 
system; 
• a Rigi-Scan and sleep 
laboratory to measure the qual i ty 
of n ight - t ime erections; 
• a dynamic infusion caver-
nosometry and cavernosography 
study to diagnose the interact ion of 
i n f l o w and out f low of hlood during 
an erection; 
• and an arteriogram to ident i fy 
blockages i n the arteries. 
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An old taboo is banished 
To put into perspective the stigma 
that impotence has carried w i t h i t for 
so many years, a December 1988 Time 
magazine article on the w o r k of U H 
and others around the country marked 
the first t i m e the magazine had ever 
reported on impotence. 
The reason for the slow develop-
ment of this f ie ld centers around 
people's unease i n disclosing sexual 
problems, and as a result, science's i n -
abi l i ty to investigate a disease that few 
people w o u l d acknowledge existed. 
It wasn't u n t i l the late 19th century 
that Dr. Sigmund Freud first explained 
and treated various sexual dysfunc-
i ions i n men and women. U n t i l that 
pn\u\, h()\w\, sexual ptobleins had not heen investigated and were eon-
sidercd taboo. 
More than f i f t y years later, i n 1948, w h e n Dr. Al f red Kinsey published 
his controversial Sexiui] Behavior in the Human Male, sexual problems 
were s t i l l considered too private to discuss, or embarrassing to admit . In 
bis book, Kinsey set forth detailed i n f o r m a t i o n on h u m a n sexual behavior 
compiled from sciemific surveys of 18,500 men and w o m e n . This showed 
that sexual problems were indeed widespread and there was a silent 
audience that needed informat ion . As a result of his pioneering M ork, 
however, Kinsey was maligned and labeled a moral degenerate. 
When sex-therapy specialists Drs. W i l l i a m Masters and Virginia 
Jolm.soii addressed impnienee i n their landmark 1966 book Human Sexual 
Response, tbe topic s t i l l was not publ i c ly w e l l received. But the high-
volume sales of the book showed that America m i g h t f ina l ly be ready to 
talk abotit its -,e.xual problems. 
In 1970, I )r. Krane helped to f o r m the Male Reproductive Center to 
treat impotence, despite the fact that i t was wide ly considered 
psyclm.ucnie in nature; a bold statement for impotence as a physiological 
condit ion. 
But impoienee is no longer taboo. Last fa l l , the Univers i ty Hospital 
hosted the T h i r d Biennial Wor ld Meet ing on Impotence. A t the con-
ference. Dr. Masters himself acknowledged that he "couldn't have heen fur-
ther from the t r u t h " w i t h respect to his 1966 c la im that impotency was al-
most completely psychological. 
Many approaches to treatment 
Today, several effective treat-
ments have emerged, and some 
men actually may have a choice of 
therapies. 
• A method that often is the 
treatment of choice is drug-injec-
t i o n therapy, w h i c h was first used 
at U H i n 1983. Currently, ap-
proximately 30,000 American men 
and 100,000 men around the w o r l d 
inject their penises w i t h chemical 
drugs—papaverine hydrochloride, 
phentolamine mesylate or pros-
taglandin E—that permit an erec-
t i o n . The medication mimics the 
neurological impulse needed to 
relax and dilate the smooth muscle 
of the penis. 
I n 1983, the Reproductive 
Center in i t ia ted its Pharmacologic 
Erection Program (PEP) to offer i n -
jection therapy. Currently, the 
PEP program is one of the largest of 
its k i n d i n the U.S., w i t h more 
than 660 patients ranging i n age 
f r o m 18 to 89. Nearly 40 percent 
of the program's patients are f rom 
out-of-state or overseas. 
A l t h o u g h the thought of a penile 
injection makes most men wince, 
U H urologie nurse c l inical coor-
dinator Terry Payton, R.N. , insists 
that "the pain is m i n i m a l because 
the needle is very small . A n d if i t 
were really that painful , we 
w o u l d n ' t have 660 men i n our 
program." 
Injections, w h i c h patients w i l l 
administer as often as instructed 
by their program supervisor, such 
as Payton, are given before inter-
course and last between 45 
minutes and one and one-half 
hours. 
• A n innovative method that 
Coldstein has employed i n over 
250 eases is vascular reconstruc-
tive surgery, w h i c h can correct 
both circulatory and leakage 
problems i n the penis. 
Typical ly, a f o r m of "bypass" 
surgery—similar to that w h i c h 
relieves blocked coronary arteries— 
is performed on patients w i t h 
penile artery blockage to restore 
adequate blood f low. This proce-
dure uses sections of an abdominal 
artery, w h i c h are grafted around 
the clogged portions of the penile 
artery. Like coronary bypass 
surgery, however, these grafts can 
be prone to the recurrence of block-
ages. 
This type of bypass surgery— 
originally performed i n Czechos-
lovakia—has been used since 1971, 
and since 1981 at U H . Its i n i t i a l 
success was variable since i t was 
not then appreciated that s imul-
taneous venous leakages could also 
be i n h i b i t i n g erections. As a 
result, since 1984, a second opera-
tive phase to close off leakages has 
been performed when needed. 
This second phase is used when 
the damaged erectile tissue cannot 
expand enough to press against its 
surrounding casing. Under normal 
circumstances, the erectile tissue 
expands against its casing, presses 
the veins closed and stops blood 
f rom draining out of the penis. 
I n this phase, the casing sur-
rounding the erectile tissue is sur-
gically folded and stitched so that 
i t can then press the veins closed. 
I n addition, some of the veins are 
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permanently t ied off so that blood 
cannot drain f r o m certain loca-
tions of the penis during an erec-
t i o n . 
Whi le this technique has been 
successful to this point , and U H 
is cont inuing to help develop the 
procedure, Krane notes that i t is 
s t i l l i n its experimental stages 
and long-term expectations cur-
rent ly are not k n o w n . 
Older patients usually opt for 
injection therapy over surgery. 
Surgery is more r isky for older 
men because they generally have 
less healthy vascular systems and 
erectile tissue due to the effects 
of aging. 
I n addition, because the penile 
arteries are one-tenth the size of 
coronary arteries, this technique 
is extremely delicate. 
• Vacuum devices, w h i c h draw 
blood into the penis, also are used 
to produce erections. Once the 
penis f i l ls w i t h blood and be-
comes rigid, rubber bands are ap-
plied to act as a tourniquet and 
keep blood f r o m escaping; they 
can be left i n place for about a 
half-hour. 
Both injection therapy and 
vacuum devices w o u l d appear to 
Many patients favor implants, which, 
although irreversible, are successful in 90 
percent of cases. New inflatable (above) 
and non inflatable implants are more com-
fortable tban previous devices. 
prohibi t the spontaneity of inter-
course, but Payton points out that 
"both techniques can give plenty 
of t ime to mainta in an erection 
before intercourse, and don't for-
get, these men otherwise w o u l d 
have no chance at sexual i n -
t imacy." 
• T w o other potential treat-
ments that are now being used 
sparingly to relieve blocked 
penile arteries are balloon an-
gioplasty and endarterectomy vas-
cular surgery. Balloon angioplas-
ty widens arterial blockages i n 
the same way that i t widens 
coronary artery blockages. Whi le 
this technique is i n c l inical use 
w i t h patients at one other ins t i tu -
t i o n i n the U.S., the U H Urology 
Research Laboratory currently is 
studying its effectiveness and 
safety i n animal models. 
A n endarterectomy involves 
scraping the blockage f r o m inside 
the artery i n order to relieve poor 
blood f low. However, Goldstein 
feels that this procedure is 
l i m i t e d to only certain patients 
and its long-term effects may not 
be as beneficial as other ap-
proaches. 
• Another opt ion is a penile i m -
plant. A l t h o u g h usually a last 
resort w i t h irreversible results, 
implants are s t i l l favored by 
many older patients, since 90 per-
cent of the procedures are success-
f u l . U H has studied the efficacy 
of new types of inflatable and non-
inflatable implants that w o u l d be 
more comfortable for patients. 
Goldstein lastly points out that 
some patients may choose to 
have a psychological evaluation 
to identi fy and come to terms 
w i t h the roots of the problem. 
St i l l others may do nothing at al l , 
since many men accept or are un-
affected hy their impotency. 
The role of research 
While there are several other i n -
st i tut ions i n the country that 
treat impotence, few have basic 
laboratory research to support 
their c l inical services. Today, the 
U H Urology Research Laboratory 
is the largest impotence lab i n 
the country, i n terms of funding. 
According to urology 
laboratory director Inigo Saenz 
De Tejada, M . D . , "a better and 
more complete understanding of 
the biochemistry and physiology 
of normal erections is essential 
before appreciating how disease 
influences this physiology." 
Lor the last three years, the 
laboratory (under the direction of 
Saenz De Tejada and i n collabora-
t i o n w i t h fel low researchers 
A b d u l Traish, Ph.D., M a r y Pat 
Carson, Ph.D., and Richard 
Cohen, M.D.) has focused its ef-
forts on the indiv idual com-
ponents of impotency hy inves-
tigating the local physiological 
mechanisms that cause erections, 
such as that of the smooth 
muscle of the penis. 
"While injection therapy effec-
t ive ly m i m i c s the neurological 
reaction to relax the smooth 
muscle, we don't k n o w what a l l 
the factors are that influence the 
muscle," says Saenz De Tejada. 
"If c l inical applications are to he 
found, we first must k n o w exact-
ly what makes the smooth 
muscle dilate to cause an erec-
t ion , and what causes i t to con-
strict to the flaccid state. Once 
we understand this, we w i l l have 
taken another step toward treat-
ing the overall problem." 
A n i m a l disease models, 
developed hy Kazem Azadzoi, 
M . D . , are now being used to 
study w h y atherosclerotic-in-
duced impotence happens, or 
w h y penile arteries become block-
ed i n the first place. This pivotal 
animal model study w i l l hopeful-
l y yie ld in format ion that w i l l 
help physicians to understand 
and further m i n i m i z e the effects 
of impotence. 
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TREATING 
MALE 
INFERTILITY 
A better chance 
at parenthood 
/
t has heen estimated 
that up to one i n five 
American couples are 
unahle to have children 
hecause of i n f e r t i l i t y . 
A l t h o u g h the problem of infer-
t i l i t y has heen a tragic fact of l ife 
for couples f r o m the dawn of 
c ivi l izat ion, only i n recent times 
has medical science had any suc-
cess i n dealing w i t h i t . 
For centuries, w o m e n have 
borne the blame for a couple's i n -
abi l i ty to have children. But ac-
cording to U H urologist Robert D . 
Gates, M . D . , a male i n f e r t i l i t y 
specialist, this is a gross misjudg -
ment. "Only about one-third of 
i n f e r t i l i t y eases are solely due to a 
women's problem,- one-third 
result f r o m the couple's com-
bined f e r t i l i t y status, and one-
t h i r d are attributable to the 
man's problem," he says. 
The Univers i ty Hospital's N e w 
England Male Reproductive 
Center has established a section 
of its program—the first and only 
one of its k i n d i n N e w England— 
that deals exclusively w i t h male 
i n f e r t i l i t y and, more important ly , 
also provides the coordination 
men and women need i n order to 
help them achieve their opt imal 
chances for pregnancy. 
Some of the new treatment op-
tions for infert i le men range f r o m 
delicate microsurgery to the surgi-
cal removal of small numbers of 
"trapped" sperm, or even electri-
cally-induced ejaculation therapy 
for men w i t h ejaculatory dysfunc-
tions. 
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How men become infertile 
While methods to treat infert i le 
w o m e n have become established, 
an understanding of how to treat 
infert i le men is just now emerging. 
"There are several reasons w h y 
male i n f e r t i l i t y has lagged behind 
as a science," says Dates. "The 
fact that i n f e r t i l i t y has tradit ional-
ly heen considered a woman's 
problem certainly is a major 
reason. But more important ly , the 
female reproductive system is 
more amenable to correction, 
whereas i f a man's testes don't 
w o r k properly, i t is d i f f i cu l t to i m -
prove them." 
It is generally accepted that i f a 
man does not produce at least 20 
m i l l i o n sperm per m i l l i l i t e r of 
ejaculate, he w i l l have d i f f i cu l ty i n 
getting his partner pregnant. 
Gates points out that many 
people assume that men who are 
infert i le are so hecause they do not 
produce enough sperm. But i t 
most often is the ac t iv i ty of their 
sperm that is the culpr i t . 
"A man can have a normal 
sperm count," states Gates, "hut if 
the sperm are not active, then 
their transport and subsequent fer-
t i l i z a t i o n may he impaired. G n 
the other hand, if a man has a 
sperm count that is s l ightly low, 
hut his sperm is very active, his 
f e r t i l i t y status is m u c h better." 
Gates estimates that 90 percent 
Normal Male Reprodnctive Anatomy 
of infert i le men suffer f r o m either 
varicoceles—enlarged veins around 
the testicle, w h i c h i n h i b i t sperm 
production and act ivi ty—or f r o m 
unexplained testicular problems 
that prevent adequate sperm 
production. 
The remaining 10 percent are 
those w i t h unusual complications, 
such as blocked tubes that 
transport sperm f r o m the testicles, 
hormonal disorders or spinal cord 
injuries. 
Managing both men and women 
"A primary reason for the rise of i n -
f e r t i l i t y rates may not he medical, 
hut possibly sociological," states 
Gates. " In other words, couples 
are now getting married and start-
ing families later, w h i c h threatens 
their abi l i ty to conceive, since 
their 'biological clocks' w o r k 
against them." 
A man's f e r t i l i t y status—which 
peaks at age 25—declines s lowly as 
he ages. A w o m a n is most fertile 
i n her mid-twenties and her abi l i ty 
to conceive decreases steadily after 
30. 
Whi le there are clinics 
throughout the country treating 
male in fer t i l i ty , few aggressively 
manage the w o m a n and the man 
i n order for the couple to have 
their best chance for conception. 
Some couples, hecause of their 
combined f e r t i l i t y statuses, have 
subsequent problems hearing 
children. To clarify, i t may he that 
both the man and the w o m a n are 
fertile enough hy themselves, hut 
their combined statuses make 
them infert i le . For example, some-
times a woman's egg production 
must compensate for a man's l o w 
sperm count or poor act ivity, or 
vice versa. 
New approaches 
The Univers i ty Hospital f irst hegan 
addressing the problem of male i n -
fer t i l i ty i n 1979 when the 
Reproductive Center opened, hut 
the addition of Gates—the only 
trained male i n f e r t i l i t y specialist i n 
N e w England—to the team of 
specialists gives t h e m an expert 
who is knowledgahle about the 
range of treatments. 
The use of medications formerly 
represented the extent of treatment 
for male i n f e r t i l i t y . "Medication 
used to he the first approach for 
men," says Gates, "hut the fact is, 
i t is very di f f i cu l t to medically 
manipulate sperm production f r o m 
a man's testes i f they don't w o r k . 
G n the other hand, a woman's 
ovaries respond very w e l l to 
medications." 
This is a crucial difference be-
tween men and women hecause a 
woman can receive therapies 
w h i c h make her over-ovulate— 
produce more eggs—and she can 
receive sperm via art i f ic ia l insemi-
nation or undergo advanced 
therapies, such as i n - v i t r o fert i l iza-
t ion . Men, on the other hand, have 
far fewer options. 
A varicocelectomy—an out-
patient surgery to correct 
varicoceles, a predominant cause of 
male infert i l i ty—resul ts i n a con-
siderable improvement i n the 
patient's sperm count and the ac-
t i v i t y of his sperm i n 60 to 70 per-
cent of cases. These men achieve 
pregnancy w i t h their partner i n 50 
to 60 percent of cases. 
There are some additional op-
tions for a small-hut-significant 
population of infert i le men. What 
is interesting about these treat-
ments is that many have emerged 
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because of gynecological advan-
ces—most notably, art i f ic ial i n -
semination and in -v i t ro fertil iza-
t i o n (IVF), and its counterpart, 
gamete intra-fallopian transfer 
(GIFT). I n IVF, the sperm fertilizes 
an egg outside the woman's body, 
w h i l e GIFT involves direct natural 
fer t i l izat ion of the egg inside the 
woman's body,- each has its o w n i n -
dications. 
Typical ly , a man's sperm are 
produced hy his testes and are 
deposited i n his epididymys (a long 
tube where sperm is stored and ma-
Couples 
are starting 
families later, 
threatening 
their ability to 
conceive' 
tures u n t i l i t is capable of fertil iza-
tion). The sperm travels f rom the 
epididymus v/ithin the vas 
deferens to the urethra, f r o m 
w h i c h i t is ejaculated. But some 
men have no vas deferens—vasal 
agenesis—so sperm becomes 
trapped i n the epididymus. 
A new procedure, called 
epididymal aspiration, allows sur-
geons to access a t i n y amount of 
v i t a l sperm that is trapped i n the 
epididymus and use i t i n conjunc-
t i o n w i t h an IVF or GIFT procc: 
dure to help achieve fer t i l izat ion. 
W i t h IVF, the sperm are com-
bined i n a laboratory culture w i t h 
a small number of eggs retrieved 
f rom the woman, w i t h the hope 
that a sperm fertilizes an egg. 
Once fert i l izat ion occurs, the eggs 
are then placed hack into the 
woman's womb. W i t h GIFT, unfer-
t i l ized eggs and sperm are placed 
directly in to a woman's fallopian 
tubes , where fer t i l izat ion occurs 
naturally. 
"This is very exciting," says 
Gates, "hut the success rate of 
epididymal aspiration is not very 
high at this point , since i t is a new 
procedure. However, i t is very en-
couraging." 
Gates currently is studying an 
alternative technique to 
epididymal aspiration, a procedure 
w h i c h at this point has only heen 
successful i n Europe. I t involves 
surgically sewing a plastic device, 
called an alloplastic spermatocele, 
to the epididymus to act as a 
sperm reservoir. When enough 
sperm is stored up, the device is 
punctured hy a t i n y needle to draw 
sperm out, w h i c h can then he used 
i n various ways to achieve pregnan-
cy. The method is now being 
tested i n the U.S. i n animal 
models; Gates hopes i t may he 
ready for human application 
w i t h i n t w o years. 
Whi le some men have no vas 
deferens, others choose to have 
theirs surgically cut to make t h e m 
infert i le . This procedure is k n o w n 
as a vasectomy and is often used as 
a form of b i r t h control . Today, 
microsurgery can reverse a vasec-
t o m y hy fusing the vas deferens 
ducts together, thus restoring fer-
t i l i t y to a good percentage of men. 
Perhaps the most excit ing infer-
t i l i t y advancement at the Repro-
ductive Center is electro-ejacula-
t i o n therapy. This therapy electri-
cally induces ejaculations i n men 
w h o cannot do so on their o w n due 
to spinal cord injuries, m u l t i p l e 
sclerosis or other problems that i n -
h i b i t normal ejaculations. 
The group that stands to benefit 
rnost f r o m this therapy are those 
men w i t h spinal cord injuries. 
Each year, 10,000 Americans suffer 
debil i tat ing spinal cord injuries; 
8,000 of t h e m are men, and most 
are young men w h o w o u l d l ike to 
father children someday. The 
Universi ty Hospital has the only 
such program i n N e w England— 
work ing w i t h the Boston Fert i l i ty 
and Gynecology Associates—and 
already has treated patients f r o m 
its N e w England Regional Spinal 
Cord Injury Center. 
"What is most significant about 
this program is that, not so long 
ago, spinal cord patients often died 
at an early age hecause of complica-
tions—so having children was the 
least of their concerns, let alone 
being an impossibi l i ty , " says 
Gates. "But as treatments have ad-
vanced, these guys now lead 
productive lives, and they can even 
have families." 
Gnce a small amount of ejacu-
late has heen obtained, the 
woman's uterus can he art i f ic ia l ly 
inseminated at an appropriate t ime 
of the m o n t h . Whi le successful 
cases of fert i l izat ion are fair ly 
rare—most often hecause the ejacu-
late has a low sperm count and 
poor sperm act iv i ty—this therapy 
can he repeated each m o n t h for an 
indefinite period. 
I t is important , however, for the 
woman's ovulat ion to he managed 
hy her gynecologist i n order for her 
egg production to compensate for 
her partner's sperm deficiencies. 
Often, the woman w i l l receive 
medication therapy to do so. 
The f ie ld of i n f e r t i l i t y is s t i l l i n 
its early stages of development. As 
new ways are found to manipulate 
the reproductive systems of men 
and w o m e n and manage their fer-
t i l i t y statuses, more i n f e r t i l i t y 
problems w i l l he solved and more 
couples w i l l have children. 
Michael R. Paskavitz 
• FOR YOUR INFORM A TION 
Dr. Dates is a 
male i n f e r t i l i t y 
specialist i n the 
U H Department 
of Urology, and 
is an assistant 
professor of 
urology at Boston Univers i ty 
School of Medicine. 
If y o u w o u l d l ike more infor-
m a t i o n on male i n f e r t i l i t y , or 
on the N e w England Male 
Reproductive Center or urology 
services at U H , call 1-800-842-
3648. 
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A Gentler Lifestyle 
New drug minimizes side effects of 
chemotherapy for cancer patients 
f or cancer patients, deal-ing w i t h the i n i t i a l diag-nosis of their disease can he devastating. Per-haps even more devas-
tating, however, are the side ef-
fects of the chemotherapy treat-
ments that some patients must 
receive to fight the disease. 
I n some ways, chemotherapy is 
a paradox: Rather than heing ahle 
to take comfort i n the fact that 
their lives are heing sustained hy 
chemotherapy, the patients often 
are drained of their w i l l to l ive hy 
the misery of its side effects. Few 
w o u l d argue that cancer therapies 
need to he more gentle. 
A new drug that controls 
chemotherapy-induced nausea and 
v o m i t i n g is currently under study 
at the Univers i ty Hospital and at 
several other medical centers 
across the country. The drug, 
called GR-C507/75 and produced 
hy Glaxo, Inc., is heing studied for 
its abi l i ty to control nausea and 
v o m i t i n g i n patients receiving 
c isplat inum; one of the most 
potent nausea-producing 
chemotherapy agents currently 
available. 
The drug GR-C507/75 is one of 
the first of a whole new class of an-
tinausea medications that appear 
to w o r k hy blocking nerve i m p u l -
ses i n the bowel and/or brain that 
trigger nausea and v o m i t i n g . 
"One major potential advantage 
of the drug is its favorable tox ic i ty 
profile; i t causes fewer side ef-
fects," says Paul J. Hesketh, M . D . , 
the principal investigator of a re-
search study on the drug at U H 
and a member of the Fvans Sec-
t i o n of Medical Oncology. "It's 
proving to he extremely effective 
as a single agent; however, we 
t h i n k that the effectiveness of the 
drug w i l l he greatly increased 
Since he began taking GR-C507/75, UH patient Stanley Grabam ofDorcbester bas been able 
to eat bis favorite foods witbout experiencing tbe nausea tbat usually accompanies 
cbemotberapy. 
when i t is used i n combination 
w i t h other antiemetic (antivomit-
ing) drugs. It's an exciting 
prospect." 
Improving qnality of life 
While GR-C507/75 w i l l not cure 
cancer or el iminate a patient's 
need for chemotherapy, i t w i l l help 
make chemotherapy treatments 
more gentle and w i l l improve the 
quali ty of life for those cancer 
patients. 
Stanley Graham, 70, of Dor-
chester, was diagnosed as having 
lung cancer last November. He 
hegan receiving chemotherapy to 
attempt to control the disease i n 
his right lung. One of the drugs ad-
ministered to Graham was 
c isplat inum. 
However, Graham never ex-
perienced any nausea or v o m i t i n g 
associated w i t h his chemotherapy. 
Prior to receiving cisplat inum, and 
then four and eight hours after 
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receiving the chemotherapy, 
Graham was given the antiemetic 
drug under study. 
N o r m a l l y , a patient receiving 
chemotherapy w o u l d he reluctant 
to eat for fear of nausea and vomit -
ing. N o t Graham, however; during 
his treatment his appetite did not 
suffer. He was ahle to enjoy some 
of his favorite foods, such as onion-
1 his drug 
promises to 
substantially 
improve the 
quality of life 
for some 
caneer patients 
and-garlic potato chips and spaghet-
t i w i t h tomato sauce. 
" I feel pretty good," Graham 
says. " I don't t h r o w up and get 
sick; I ' m very pleased." 
Studies cite drug's effectiveness 
The current U H study, sponsored 
hy Glaxo, Inc., is one of a number 
of studies heing performed nation-
ally to investigate different applica-
tions of the drug. A prior national 
study led hy Hesketh looked at the 
effectiveness of GR-C507/75 i n 
preventing nausea and v o m i t i n g as-
sociated w i t h c isplat inum during 
the first 24 hours after beginning 
chemotherapy. Fifty-five percent 
of patients experienced no v o m i t -
ing during the study period. The 
results of this study are to he 
published shortly i n the Journal of 
Clinical Oncology. 
The present major study at U H 
is comparing GR-C507/75 to 
metoclopramide, currently the 
most effective single antiemetic 
drug. A n additional study now 
under way at U H is looking at 
v o m i t i n g i n patients t w o to five 
days after receiving c isplat inum. 
D u r i n g this study, the drug w i l l he 
administered orally, rather than hy 
injection, Hesketh says. 
A future study w i l l evaluate GR-
C507/75 when used w i t h non-
eisplat inum containing 
chemotherapy. This study w i l l he 
quite important , according to Hes-
keth, as "the majori ty of people 
treated w i t h chemotherapy are not 
going to receive c isplat inum." 
Easing burden of treatment 
According to oncology research 
nurse A n n Hesketh, R .N. , GR-
C507/75 is important to nurses he-
cause i t eliminates some of the dis-
comfort patients experience w i t h 
chemotherapy. 
A n i n i t i a l study at U H last 
March experimented w i t h different 
diagnoses of GR-C507/75. Assist-
ing w i t h the study were nurses 
f r o m the Hospital 's Oncology 
U n i t — A t r i u m 7-Fast and -West— 
who were instrumental i n w o r k i n g 
w i t h the patients involved. "If we 
can make a patient's treatment any 
easier, then we are doing our jobs," 
A n n Hesketh says. She has seen 
some cases where the 
chemotherapy treatment is so 
grueling that a patient drops out of 
therapy al l together. The outcome 
for such patients, she says, is g r i m . 
"Side effects have to he m i n i -
mized i n order to motivate a 
patient to continue w i t h his or her 
treatment. I t h i n k this new drug 
w i l l help i n that area," A n n Hes-
keth says. She adds that, theoreti-
cally, "there could he a very effec-
tive anticancer therapy that is 
available, hut a patient may refuse 
to continue to receive i t hecause of 
the severe nausea and v o m i t i n g as-
sociated w i t h i t . " 
An exciting future 
According to Dr . Hesketh, Glaxo, 
Inc., w i l l most l i k e l y fi le for 
federal Food and Drug Adminis t ra-
t i o n (FDA) approval of GR-
G507/75 sometime w i t h i n the 
next t w o years. 
He is excited about the future of 
the drug. "The results have heen 
very successful to date. This new 
drug promises to substantially i m -
prove the qual i ty of life for cancer 
patients." 
Cynthia L. Paradis 
• FOR YOUR INFORMATION 
Dr. Hesketh is a 
member of the 
Hospital 's Evans 
Section of 
Medical 
Oncology, and is 
an assistant 
professor of medicine at Boston 
Univers i ty School of Medicine. 
If you w o u l d l i k e more infor-
m a t i o n on GR-C507/75 or on 
medical oncology services at 
the Univers i ty Hospital , please 
call 1-800-842-3648. 
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THE 
STONE 
CENTER 
A myriad of 
approaches to 
deai with those 
painfui stones 
BY C Y N T H I A L . PARADIS 
f ive years ago, a patient w o u l d have had to hear not only the pain of a kidney stone or gallstone hut also the 
pain of surgery and a long convales-
cence. The surgical answer, now 
used sparingly, is fast heing chal-
lenged hy modern technology. 
Modern stone treatment is as 
diverse as i t is progressive. A t the 
Univers i ty Hospital Stone Center, 
a wide range of innovative non-
operative methods for treating u r i -
nary and hi l iary stones are avail-
able and are proving to he safe, effi-
cient, cost-effective and, perhaps 
most important ly , less painful or 
traumatic for patients. For those 
w i t h stones that exhibit 
symptoms, the treatment options 
are numerous—from medication 
therapy and dietary adjustment to 
the use of lasers and shock waves. 
W i t h this myr iad of treatments, 
patients are assured that they w i l l 
receive the treatment most ap-
propriate for them. 
Fach new treatment method is 
based on " l i thotr ipsy," the crushing 
or dissolving of stones i n the k i d -
ney, ureter or hi l iary tract. Depend-
ing upon the size, number, location 
and composit ion of the stones, 
these approaches also are effective 
i n combatting recurrence, a com-
m o n problem among stone patients. 
The Univers i ty Hospital has 
played a leadership role i n develop-
ing laser l i thotr ipsy and other treat-
ments. A recent addit ion to the 
Hospital's arsenal of techniques— 
extracorporeal shock wave 
l i thotr ipsy (FSWF)—completes a 
kaleidoscope of options for treating 
stones at the Stone Center. FSWL 
non-invasively fragments urinary 
stones and gallstones using high-
energy shock waves. 
The Hospital 's involvement i n 
one early treatment m e t h o d — 
gallstone dissolution—dates hack 
more than 10 years, to when 
Donald Small, M . D . , the director of 
Boston Univers i ty School of 
Medicine's Biophysics Inst i tute, he-
came the first researcher i n the 
country to develop techniques to 
chemically dissolve gallstones. 
I n the early 1980s, U H urologist 
Richard K. Bahayan, M . D . , and 
A l a n Greenfield, M . D . , of U H ' s In-
terventional Radiology Depart-
ment, were among the first 
physicians i n N e w Fngland to 
remove kidney stones per-
cutaneously, hy passing scopes 
through small openings i n the 
flank, directly in to the kidney. 
This procedure is now performed 
under local anesthesia and has vir-
tual ly replaced the need for open 
surgical removal of stones. 
Treating nrinary stones 
The term "urinary stone" includes 
both kidney stones and ureteral 
stones, since they are both of 
similar composition, hut are dist in-
guished hy their location. 
Kidney stones are composed 
pr imar i ly of calc ium and are 
formed when crystals of a sugar-
protein substance stick together. 
They can he as small as a grain of 
salt or as large as a softhall. I t is es-
t imated that hy age 70, up to 10 per-
cent of the American population 
w i l l have suffered f r o m kidney 
stones. 
"If a kidney stone is under five 
mi l l imeters i n diameter, a person 
w i l l most l ike ly pass i t w i t h o u t 
treatment; however, if a stone is 
over eight mi l l imeters i n diameter, 
i t is u n l i k e l y to he passed," 
Bahayan says. 
Physicians at the Univers i ty 
Hospital are now routinely employ-
ing lasers to pulverize ureteral 
stones less expensively and w i t h 
less hospitalization for the patient. 
John Crandell (not his real 
name), 53, is a Boston business ex-
ecutive who is i n excellent shape. 
He played racquethall three times a 
week, watched what he ate and en-
joyed overall good health. One 
morning at work , however, Cran-
dell hegan experiencing sharp pains 
i n his lower abdomen. Because the 
i n i t i a l pains weren't severe, he 
tr ied to ignore them. When he got 
to the point where he could hardly 
sit at his desk, he became con-
cerned. 
Grandell was taken to a hospital 
The laser 
is so delicate 
i t can de shell 
an egg without 
harming the 
th in membrane 
inside the shell' 
emergency room. After an ex-
aminat ion and x-ray, he was diag-
nosed as suffering f rom urinary 
stones; a stone the size of a dime 
was lodged i n his lower ureter. 
Depending on the specific medi-
cal circumstances of his case, 
Crandell's stone may he best 
treated hy ureteroseopy and laser 
l i thotr ipsy, Bahayan's preferred 
method of treatment. He has heen 
using laser l i thotr ipsy on ureteral 
stone patients since June 1988 and, 
according to h i m , "If I had a choice. 
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r d use the laser i n every ease,- it 's 
an excellent form of treatment." 
A physician passes a small 
ureteroscope through the bladder 
and in to the ureter. He visualizes 
the stone and passes a laser fiber 
through the scope to make contact 
w i t h the stone. The stone is pul -
verized using the Candela tunable 
pulsed dye laser, w h i c h produces 
an intense hurst, or pulse, of laser 
energy. Once disintegrated, the 
fragments are removed hy the 
physician or passed hy the patient. 
"The laser produces a high de-
gree of energy w i t h l i t t l e heat. I n 
m y opinion, i t is safer than any 
other means of fragmentation," 
Bahayan says. 
Currently, the procedure is per-
formed under general anesthesia 
and the patient is hospitalized for 
one to t w o days. However, 
Bahayan says he hopes eventually 
to he ahle to perform the procedure 
under local anesthesia. " I 'd l ike to 
treat patients for kidney stone dis-
ease on an outpatient basis. The 
patient can come i n , have his 
or her stone removed and go home 
that same day; that's m y ul t imate 
goal," he says. 
The recent acquisition of the 
Sonolith 3000 extracorporeal shock 
wave l i thotr ipter gives the U H 
Stone Center the latest generation 
of shock wave l i thotr ipsy. Whi le 
the first generation of ESWL re-
quired that patients he submerged 
i n a hath water tank during treat-
ment, the Sonolith 3000—manufac-
tured hy Technomed International 
of France—fragments stones w h i l e 
the patient is ly ing on a table. 
FSWF is performed under i n -
travenous sedation and uses 
ultrasound, rather than x-ray 
fluoroscopy, to locate a patient's 
stone. Al though the procedure 
w i l l he performed i n i t i a l l y on an 
overnight basis, Bahayan says he 
hopes to use i t i n kidney stone 
patients on an outpatient basis. 
"This (shock wave) treatment 
w i l l provide the Hospital w i t h a 
noninvasive treatment for kidney 
stones and a m i n i m a l l y invasive 
treatment for ureteral stones. I t 
gives us a f u l l spectrum of treat-
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ment for urinary stones w i t h o u t 
open surgery," Bahayan says. "Our 
a im is to provide a c o m m u n i t y ser-
vice not only to patients, hut to 
urologists i n the area who w i s h to 
treat patients using the ESWL at 
the Stone Center." 
Making progress against gallstones 
"Right now," points out Desmond 
H . Birkett , M . D . , chief of the Sec-
t i o n of Surgical Castroenterology, 
"there is only one procedure for 
treating gallstones—a cholecystec-
tomy, or complete gallbladder 
removal—hut several new ap-
proaches should emerge i n the very 
near future. A n d these new proce-
dures w i l l continue to he refined 
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over the next five to 15 years." 
Most gallstones are composed of 
cholesterol, w h i l e some are a m i x -
ture of cholesterol and calcium. 
Gallstones, l ike kidney stones, 
vary i n size and composition, hut 
unl ike kidney stones, they cannot 
he passed. I t is estimated that 30 
percent of Americans w i l l have had 
gallstones hy age 70. Physicians at 
the Stone Center are investigating 
several new ways to r id patients of 
gallstones w i t h o u t surgery. 
The Univers i ty Hospital , along 
w i t h the Cedars-Sinai Medical 
Center i n Los Angeles, and the 
Univers i ty of Indiana Medical 
Center, is enrolled i n a study 
funded hy the Candela Laser Cor-
poration of Wayland, Mass., to ob-
tain FDA approval of laser l i t h o t r i p -
sy i n patients w i t h gallstones. The 
study, headed hy Birkett and David 
R. Cave, M . D . , Ph.D., a member of 
the Fvans Section of Castroenterol-
ogy and chief of the Univers i ty 
Hospital's Endoscopy U n i t , w i l l 
evaluate the laser's safety and effec-
tiveness. 
I n the study, the laser was used 
for the first 20 months i n animal 
models, and Cave says prel iminary 
results have shown that "very l i t t l e 
or no subsequent treatment w i l l he 
required" using the laser. I n fact, 
the laser fragments the stones so 
thoroughly that up to 90 percent of 
the pieces w i l l he removed f r o m 
the gallbladder thereby m i n i m i z i n g 
the stones' recurrence, w h i c h often 
can he a significant problem. Cave 
calls lasers "an excit ing new direc-
t i o n for stone treatment. The laser 
is so delicate that i t can deshell an 
egg w i t h o u t harming the t h i n 
membrane inside the shell." 
The acquisition of the Sonolith 
3000 offers another treatment op-
t i o n to U H gallstones patients, al-
though the use of FSWL for treat-
ing gallstone patients has not yet 
received approval hy the federal 
Food and Drug A d m i n i s t r a t i o n 
(FDA). Birkett and Cave expect to 
use i t only on an experimental 
basis i n gallstone patients, hopeful-
ly w i t h i n six months. Cave also 
points out that FSWL w i l l l i k e l y he 
used i n conjunction w i t h other 
gallstone treatments—such as 
chemical dissolution—since the 
size, number and composit ion of 
gallstones are such that shock 
waves alone sometimes cannot suf-
f ic ient ly fragment the stones. 
However, shock wave l i thotr ipsy 
is indicated only for gallstone 
patients w h o have up to three 
stones, and i t takes a number of 
months for the subsequent dissolu-
t i o n of stones. For patients w i t h 
m u l t i p l e gallstones, Birkett is inves-
tigating a new alternative techni-
que—electrohydraulic l i thotr ipsy 
(FHL)—which, l ike FSWL, uses an 
electrically-induced shock wave 
(similar to that of a car's spark plug) 
to pulverize the stone. FHL is a 
m i n i m a l l y invasive procedure—per-
formed under local anesthesia— 
whereby a doctor inserts a catheter 
into the gallbladder and then passes 
a flexible wire probe through an en-
doscope. When mixed w i t h saline, 
w h i c h acts as an electrical conduc-
tor, the wire probe causes an i n i t i a l 
spark and then a shock wave to 
smash the stone (the effect is 
similar to that depicted i n the 
photograph on the hack cover of 
Progress). Since gallstones are 
l i teral ly trapped i n the gallbladder, 
the fragments must he removed 
w i t h a basket guided into the 
gallbladder. 
If FHL is u l t imate ly accepted as 
a method for use i n patients, i t w i l l 
l ike ly he introduced as an overnight 
procedure, hut Birkett believes i t 
could eventually he a same-day pro-
cedure. 
"What we're looking at are new 
ways of approaching kidney stone 
and gallstone disease that w i l l he 
cost-effective, can m i n i m i z e a 
patient's t ime i n the hospital, and j 
d i m i n i s h his or her discomfort," 
Cave says. 
Bahayan, Birkett and Cave share 
the same ul t imate goal at the Stone 
Center: offering the safest, most 
comfortable and most effective 
treatment possible. 
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An interview about steroids with Robert E. Leach, M.D. 
A t the 1988 Summer Olympic Games i n Seoul, Korea, Canadian sprinter Ben Johnson made the term "steroids" a household word when he was stripped of his gold medal after testing positive for illegal steroid use. Just hours earlier, Johnson had set a new wor ld record i n the 100 meter dash, thus earning the t i t le 
"the fastest human being alive." 
Unfortunately, steroids aren't a problem facing only world-class 
athletes. A recent study published i n the Journal of the American 
Medical Association (JAMA) estimated that as many as half a m i l -
l i o n high-school athletes may he taking steroids, and further 
revealed that more than one-third of surveyed users first took 
steroids at 15 years of age or younger. 
As head of the Sports Medicine Council of the U.S. Olympic 
Committee, Dr. Robert E. Leach was on hand to see the steroid 
drama unfold at the Summer Games. Progress writer Paula 
Cil l igan spoke to Leach, chief of the U H Department of Orthopedic 
Surgery, about his views on steroid use by athletes, the foremost 
medical and ethical issue i n the sports w o r l d today. 
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Robert E. Leach, M.D. 
Progress: What are steroids, specifi-
cally anahoiic steroids? 
Leach: Steroids are hormone-l ike suh-
stances produced normal ly hy the 
hody. They have a variety of uses. I n 
terms of athletic use and i l legal i ty, 
we are ta lk ing ahout male anahoiic 
steroids, such as testosterone, w h i c h 
is a male hormone. Basically, this 
steroid causes a hui ld-up or retent ion 
of nitrogen. Athletes use synthetic 
analogs of natural ly oeeuring hody 
hormones, such as testosterone, w i t h 
the concept heing that hy retaining 
nitrogen, and doing constant exer-
cises, one can h u i l d muscle mass and 
become stronger, result ing i n a better 
performance. 
Progress: What are not-so-
heneiicial short- term eiiects? 
Leach: Water retention and emotion-
al changes are a couple. A woiuan 
might experience "masculinizing" 
traits, such as a voice change, hair 
loss, sk in problems. In men, there 
m i g h t he a change i n sexual ac t iv i ty . 
Progress: H o w ahout long-term 
eiiects? 
Leach: Right now, we do not honest-
l y k n o w what the long-term eiiects of 
anahoiic steroids are, since anahoiic 
steroid use has not heen around long 
enough for longi tudinal medical 
studies to have heen completed. 
Anecdotally, we k n o w there have 
heen people i n their early 30s w h o 
were heavy steroid users and have 
had major heart attacks and died or 
have had severe artherosclerosis. We 
k n o w that transient changes occur i n 
the liver, perhaps i n the kidneys; we 
k n o w hlood pressure can rise,- we 
k n o w some people have problems 
w i t h sexual potency and ster i l i ty ; and 
we k n o w some people have exhibited 
bizarre, psychotic behavior. Basically 
we k n o w there is a chance that a per-
centage of those taking steroids w i l l 
he physically harmed. 
w h a t we don't k n o w is how long 
is " long-term," or if potential damage 
is related to dosage. If y o u took 
steroids for four weeks once, w i l l that 
hurt you? I don't know, hut w i t h 
most drugs, the longer and more 
often y o u take them, the more 
trouble y o u have. 
We t h i n k that most of the t i m e it 's 
possible to reverse these changes, hut 
we don't have any long-term studies 
to say so. 
Progress: Are there medical reasons 
w h y someone w o u l d take anahoiic 
steroids? 
Leach: You could give anahoiic 
steroids to someone w h o was starving 
or having trouble eating. I t w o u l d 
prohahly induce a better appetite and 
a l low t h e m to hold nitrogen, thereby 
bui ld ing up blocks of tissue. 
Anahoiic steroids lu ight also he of 
some value for burn patients. But for 
athletes, there really aren't any 
reasons other than to h u i l d muscle. 
Progress: H o w long have athletes 
heen using steroids? 
Leach: I n the m i d 50s, members of a 
U.S. w e i g h t l i f t i n g team hegan notic-
ing that weight l i i ters f r o m the 
socialist-hloc countries, part icularly 
the Soviet U n i o n , were making 
tremendous strides i n the sport. 
They looked stronger, l i f t ed more and 
i n most ways were far ahead of the 
i rest of the w o r l d . W o r d of steroid use 
; hegan f i l t e r ing out, hut for a long 
i t i m e i t really stayed w i t h i n that par-
t icular group of athletes. 
I w o u l d say that usage hy U.S. ath-
I letes came in to heing i n the m i d to 
^ late 50s, gained impetus during the 
60s and became a problem i n the 70s. 
We didn ' t really t ry to deal w i t h i t 
u n t i l ahout the last 12 years. A n d i t 
has progressively become more of a 
problem because advances i n the way 
steroids are used hy athletes have out-
paced the knowledge and studies of 
physicians. 
Progress: What athletes are most 
l i k e l y to he steroid users? 
: Leach: Athletes w h o benefit f r o m i n -
creased strength w o u l d be the most 
l i k e l y candidates. Discus-throwers, 
; shot-putters—those w h o participate 
; i n track and f ie ld events are thought 
to have used steroids. Bodybuilders 
are also suspect; i n fact, the inference 
is that almost a l l male and female 
bodybuilders use steroids. Another 
aspect of steroid use is the belief that 
steroids a l low athletes to t ra in more 
heavily and shorten the recovery 
period. We k n o w that runners, bo th 
marathoners and sprinters, and 
cyclists have used them to help 
recover faster. 
Progress: Was there a noticeable 
: problem w i t h steroid use at the 1988 
I Olympics? 
\: The problem (at the O l y m -
pics) was not noticeable i n the sense 
of catching people. The problem was 
and is: We k n o w we're catching a 
few people; we k n o w we're seeing 
people w i t h absolutely incredible 
muscle development. Do we look at 
t h e m and say, " I believe those people 
are cheating." They w o u l d say, " I ' m 
I t ra in ing very hard and it 's unfair of 
i y o u to say that." This is the d i l em-
l ma. There is the feeling that cheat-
ing is going on, that the athletes have 
learned to heat the system. 
j 
I Progress: Is steroid use illegal? 
! Leach: Steroids are i l legal to use 
( under the Internat ional O l y m p i c 
Commiss ion rules and any games 
that are r u n under those auspices, al-
though only some of these events 
16 T H E U N I V E R S I T Y H O S P I T A L 
w i l l test the athletes. As o i this mo-
ment, steroids are not i l legal i n 
professional sports, but that possibly 
may change i n professional football , 
where i t is thought that an incredible 
number o i l inemen and linebackers 
use steroids. We are aware that col-
lege football players and even high 
school football players use steroids as 
w e l l , and many people t h i n k these 
numbers are higher than is generally 
believed to he. 
Some people say that taking 
steroids is no different than using a 
better pole for the pole vault , or heing 
ahle to eat better food than another 
athlete and therefore grow stronger. 
But I t h i n k it 's cheating and it 's heat-
ing the system. 
Progress: Where do athletes obtain 
steroids? 
Leach: Apparently they are easy to 
get. Sometimes they are obtained 
f r o m doctors, sometimes f r o m phar-
maceutical companies. Most get 
t h e m hy s imply going to w e i g h t l i f t i n g 
or health clubs and seeking out some-
one w h o is i n t o muscle bui ld ing . 
There seems to he a pipeline to ob-
ta in steroids. 
Progress: What is the normal proce-
dure athletes go through when taking 
steroids to prepare for an event? 
Leach: First, they t ry to figure out 
w h e n the steroids w i l l he cleared 
f r o m their hodies. Then they t ra in for 
the event, using steroids along w i t h 
r u n n i n g and l i f t i n g , up u n t i l the t ime 
i t takes for the steroids to leave their 
hodies. When they stop using 
steroids, they might lose some 
strength, hut w i l l s t i l l keep a lo t that 
they've b u i l t up, so hy the day o i the 
compet i t ion, they are "clean." 
However, they are playing a f o r m o i 
athletic roulette hy bett ing they 
w o n ' t get caught. 
I n the case o i Ben Johnson, (the 
O l y m p i c athlete w h o was stripped o i 
his gold medal), he appeared to he 
playing that game, and got caught. I t 
w o u l d appear, look ing at h i m now, 
that he probably had taken steroids 
before. Certainly he had taken t h e m 
sometime before the Olympics , and 
he was not clean w h e n he was there. 
Progress: H o w accurate is the testing? 
Leach: The testing for steroid use is 
very accurate and sophisticated. One 
problem w i t h testing is that i t may 
not he not possible to check al l the 
urine samples heing picked up at one 
major compet i t ion. Testing is compl i -
cated and expensive. Sometimes 
there may not he enough machines 
available. Other times the results are 
not reported hecause the officials do 
not want to r u i n the compet i t ion . 
But the testing procedure itself is very 
accurate. I t distinguishes anahoiic 
steroids f r o m other substances, such 
as b i r t h control pi l l s or other athlet i -
cally legal substances. 
I t is h ighly u n l i k e l y for athletes 
w h o are caught to admit to taking 
steroids, hecause the m i n u t e they do, 
they are banned f r o m compet i t ion for 
t w o years. They are also looked upon 
hy the general public as heing had 
people, so it 's m u c h easier for t h e m 
to say they were set up, as Johnson 
did. But the testing is good; i t is fair,-
and everyone w h o is caught taking 
steroids always denies i t . 
Progress: If the consequences are so 
grave, w h y w o u l d an athlete jeopard-
ize h i m or herself? 
Leach: I t h i n k for many o i them, the 
gains are so great they are w i l l i n g to 
r u n the risk. I n fact, before the last 
Olympics , a group o i competitors 
were asked: If y o u thought you could 
w i n a gold medal hy taking steroids, 
hut w o u l d die ten to t w e n t y years 
afterwards as a result, what w o u l d 
y o u do? N i n e t y percent said they 
w o u l d take the steroids. 
Progress: Is i t possible for athletes to 
reach the same levels w i t h o u t using 
steroids? 
Leach: This is the big problem. 
Some studies say yes, some say no. I 
know o i several athletes w h o were 
clean w i t h o u t doubt, worked their 
tails off and set personal records i n 
their sport o i w e i g h t l i f t i n g . However, 
i t appears to he easier to accomplish 
w i t h steroids, al though not absolutely 
everyone w h o takes steroids sees an 
increased performance. Steroids do 
increase strength, hut not always per-
formance. 
Progress: Do y o u see any way the 
problem o i steroid use can he 
eliminated? 
Leach: The key is random testing. I 
really t h i n k there always w i l l he ath-
letes w h o w i l l t ry to get better hy 
whatever means they can. To ask an 
athlete not to take steroids just isn' t 
enough. You'd prohahly f i n d that 
most athletes do not want to take 
steroids, hut w i l l stop only if they can 
he sure their competitors also w i l l 
stop. 
There are m i l l i o n s o i athletes w h o 
are clean, and the vast major i ty oi 
competitors i n the Olympics don't 
take steroids, yet we ta lk ahout i t a l l 
the t ime . I t is m y iiupression now 
that the socialist nations, especially 
the Soviet U n i o n , w h o were the 
major users originally, are t ry i ng to 
"clean up their act," and are not 
happy ahout their athletes' use. The 
U.S.S.R. and the U.S. are t ry ing to 
come to some agreement on prevent-
ing steroid use, hut I t h i n k what is 
needed is to catch enough people to 
make i t too dangerous for the ath-
letes. I believe random testing is the 
only way to accomplish this. 
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New blood therapy is effective against leukemia, and shows 
BY P A U L A A. G I L L I G A N 
j^m new f o r m of l i g h t - i n -
^ P H duced therapy, called 
^ v _ H photopheresis, is now 
^ H ^ H being used hy c l inical re-
MW • searchers at the Univer-
sity Hospital to treat patients w i t h 
an u n c o m m o n hut fatal type of 
leukemia, k n o w n as Sezary's 
syndrome. Equally as excit ing as 
its current success, however, is the 
promise photopheresis holds for 
treating a number of other diseases 
as w e l l . 
Howard Koh, M . D . , F.A.C.P., a 
member of the dermatology and 
medicine departments, and the 
School of Public Health, is the pr in-
cipal U H investigator. He explains 
photopheresis as "a process i n 
w h i c h a drug (psoralen), fo l lowed 
by l ight w h i c h activates that drug, 
is used to k i l l cells." 
More specifically, a patient f irst 
ingests the drug psoralen, then his 
of her hlood is removed w i t h the 
use of a photopheresis machine. 
The blood then is irradiated w h i l e 
s t i l l outside the body. This irradia-
t i o n activates the drug, w h i c h , i n 
t u r n , k i l l s the cancer cells. After 
the process is completed, the 
hlood, containing the damaged 
cells, is recirculated in to the 
patient's body. 
A func t ion as important as k i l l -
ing the cancer cells outside the 
hody is the reinfusion of the blood 
back in to the patient. "This some-
how seems to st imulate the body's 
o w n i m m u n e system to k i l l more 
cancer cells, although i t is not real-
ly clear how or w h y this happens. 
We feel a l i t t l e h i t humbled be-
cause we don't completely under-
stand how i t works," says Koh. 
The Hospital f irst became i n -
volved i n the program about a year 
ago, w h e n the machine used i n 
photopheresis was shown to be ef-
fective for treating Sezary's 
syndrome. Dr . Barbara Gilchrcst, 
chief of the Hospital's Department 
of Dermatology, appointed Koh to 
lead U H ' s effort i n this f ie ld he-
cause of his expertise and training 
i n dermatology and hematology/on-
cology as w e l l as internal medicine. 
Today, the Hospital is one of 
only 15 medical centers i n the 
country that have photopheresis 
capabilities, and the only one 
nor th of Yale-New Haven (Conn.) 
Hospital . There have heen about 
20 patients referred to U H for treat-
ment since the program began, 
w i t h 10 being actively treated right 
now. 
The disease for w h i c h 
photopheresis is currently ap-
proved and seems to be the most ef-
fective method of treatment is 
Sezary's syndrome. This disease 
previously was extremely di f f i cu l t 
to treat using the tradit ional can-
cer options of chemotherapy 
and/or radiation therapy. As the 
most severe f o r m of sk in cancer— 
called cutaneous T-cell l y m -
phoma—Sezary's syndrome causes 
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extreme redness and scaling of the 
skin, and the malignant cells 
migrate f r o m the sk in in to the 
blood, causing a f o r m of leukemia. 
Hence, photopheresis is used as 
treatment for cutaneous T-cell l y m -
phoma during the most extreme 
phase of this disease, when i t has 
moved in to the blood. 
Koh believes that Sezary's 
syndrome is among the most 
debil i tat ing diseases he has ever 
seen. "This very aggressive f o r m of 
cancer is not only u l t i m a t e l y fatal, 
but also has day-to-day m o r b i d i t y 
as we l l , w i t h constant sk in discom-
fort and pain. It's hard to t h i n k of 
any other cancer that has this de-
gree of constant suffering," he says. 
"We are delighted to be able to 
offer patients this treatment." 
A major study i n the New 
England Journal of Medicine last 
year showed that nearly 75 percent 
of people w i t h Sezary's syndrome 
w h o received photopheresis treat- j 
ment benefited f r o m i t . But, as 
Koh cautions, the procedure is not 
a cure. "Photopheresis significant-
l y helps these people, and puts 
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their disease into remission, w h i c h 
means that their debil i tat ing 
symptoms improve. Right now, i t 
looks l ike the treatments prolong 
survival, but we w i l l have to wai t 
a long t ime to see whether i t is 
really curative." 
U H patients afflicted w i t h the 
disease have heen, for the most 
part, ecstatic over their improved 
conditions through photopheresis, 
according to Koh. "There are 
several people we've heen ahle to 
help quite a bi t . Before undergoing 
this treatment, they constantly 
i tched and had skin discomfort 
and pain. N o w , however, they've 
improved a great deal—they have 
almost normal sk in and are feeling 
the best they have i n years. They 
are very satisfied patients." 
The Pros and Cons 
U n l i k e tradit ional chemotherapy, 
the drug used i n photopheresis, 
psoralen, is v i r t u a l l y non-toxic, so 
there are almost no side effects, 
such as nausea and v o m i t i n g . I n 
cases where photopheresis has not 
been effective i n p u t t i n g the dis-
ease in to remission, patients under-
going the treatments are not 
harmed hy the process either; so 
w h i l e such patients aren't being 
helped, neither do they suffer any 
serious adverse effects. This 
m i g h t encourage those Sezary's 
syndrome patients w h o may he 
afraid to t ry new forms of treat-
ment to look into photopheresis as 
an alternative method, since there 
are almost no risks involved. 
One drawback of photopheresis 
treatment, however, is its lack of 
speed i n taking effect. I n fact, i t 
may take f r o m four to six months 
before any improvement i n the 
condit ion occurs. For some 
people, that may he too late,- they 
may simply be deteriorating too 
quick ly for the treatment to w o r k . 
Only through continual experience 
has Koh heen able to determine 
w h o the best patients are. This is a 
common procedure i n any new 
type of therapy. 
What is involved? 
Once a patient decides to undergo 
photopheresis therapy, he or she is 
treated on an inpatient basis. This 
occurs on t w o consecutive days 
every m o n t h . One cycle takes 
ahout five hours, and the patient 
stays i n bed during the procedure. 
Because photopheresis is an i n -
patient treatment, the costs are the 
standard D R G (Diagnosis Related 
Group) costs for sk in lymphoma. 
It may be that i n t ime, 
photopheresis w i l l he moved in to 
an outpatient setting, e l iminat ing 
the cost of hospitalization and 
thereby lowering the cost of the 
treatment. 
Perhaps the most excit ing 
prospect of al l may be the future 
implicat ions of photopheresis for a 
variety of other diseases affecting 
the i m m u n e system. "The fascinat-
ing aspect ahout photopheresis is 
that i t appears to be a new way of 
intervening i n the i m m u n e system, 
and may help us understand more 
f u l l y how the i m m u n e system 
works. We are studying the pos-
sible application of photopheresis 
to other, more common immune-
mediated diseases for w h i c h tradi-
t ional therapy may not be ade-
quate," says Koh. 
Koh and his associates have 
received research grants to do ex-
ploratory c l inical and laboratory i n -
vestigations w i t h photopheresis i n 
other diseases. For example, the 
U H researchers are now taking part 
i n a multi-center study to deter-
mine the possible effectiveness of 
photopheresis i n treating another 
f o r m of leukemia, chronic l y m -
phocytic leukemia (CLL), a more 
common type of leukemia than 
Sezary's syndrome. 
Photopheresis is also being con-
sidered as an investigative f o r m of 
treatment for rheumatoid arthrit is , 
a fair ly common f o r m of arthri t is . 
This t r ia l w o n ' t be taking place 
u n t i l some t ime i n the near future, 
but Koh hopes U H w i l l he included 
i n that study as w e l l . 
Other future uses for 
photopheresis may include apply-
ing i t to scleroderma, i n graft rejec-
t i o n or i n combination w i t h tradi-
t ional cancer therapies (radiation 
or chemotherapy). According to 
Koh, the future of this f ie ld of 
medicine seems wide open. "We 
even have a photopheresis fel low. 
Dr. Janet Wieselthier, here at U H 
now," he reveals. "It's excit ing to 
be bui ld ing a program here. It's cer-
ta inly establishing our medical cen-
ter as a referral center for 
cutaneous T-cell lymphoma and 
Sezary's syndrome, and also for 
photopheresis and its many pos-
sible future applications." 
• FOR YOUR INFORMATION 
Dr. Koh is a H H H ^ ^ ^ 
member of the ^5B||G5i 
staff of the J p * '^m 
Univers i ty M V ^ ^ ^ 
Hospital , and is H ^ ^ ^ 
an assistant ^ 
professor of 
dermatology, medieine and 
public health at Boston 
Univers i ty School of Medicine. 
If y o u w o u l d l i k e more infor-
m a t i o n on photopheresis or on 
dermatology or medical oncol-
ogy services at the Univers i ty 
Hospital , please call 1-800-842-
3648. 
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Easing 
the 
Transition 
A new Short 
Stay Unit 
makes entering 
and leaving the 
Hospital more 
comfortable 
It's 8 a.m., and you've finished 
registering for your 11 a.m. 
surgery. You're scared and al l you 
can t h i n k about is where y o u ' l l be 
wheeled to before surgery, but you 
have three more hours to t h i n k 
about it—alone. 
It's 3 p .m. and your surgery is over. 
Uncomfortable and not yet settled, 
you wai t impat ient ly i n the lobby 
of the Hospital for someone to 
pick you up and take you home. 
r hese before-and-after scenarios may sound famil iar to you if you've been an ambulatory surgery patient. I n 
hospital language, these times are 
s imply k n o w n as transit ion 
periods. But to a nervous patient 
w a i t i n g to have surgery or diagnos-
tic testing, these intervals are 
times when anxiety rules. 
A new Short Stay U n i t (SSU)— 
formed as a means of easing those 
nervous transitions—has been i n 
operation at the Univers i ty Hospi-
tal since last May. The U n i t , 
w h i c h contains twelve beds and 
six recl ining chairs, as w e l l as a 
comfortable w a i t i n g room, serves 
several purposes. 
I t is a place where patients w i l l 
come after being admitted to 
prepare for their surgery or for a 
diagnostic procedure. Fol lowing 
their procedure, patients w i l l t y p i -
cally return to the U n i t regardless 
of whether they are to be admitted 
later that day or whether they w i l l 
go home. The U n i t also offers 
patients a comfortable area to wai t 
after being discharged. 
"Short stay units for ambulatory 
patients are fairly common at 
other hospitals," says Assistant 
Director of Nurs ing Resources 
A n i t a King, R . N . "But few have 
areas where patients can wai t i n 
such a cheerful and pleasant atmos-
phere, and s t i l l have the ap-
propriate nursing care available." 
The nurses who staff the U n i t 
come f rom medical, surgical and 
Time 8:12 a.m. 
cri t ical care backgrounds and have 
cared for the many types of 
patients who use the U n i t . "Most 
of our patients are not acutely i l l , 
so the U n i t is generally a more 
healthy environment than, say, an 
intensive care u n i t , " says Cl in ica l 
Leader Donna McNamee, R.N. , a 
former Coronary Care U n i t nurse. 
"But at the same t ime, we are not 
w i t h o u t certain situations that re-
quire the skills and expertise of our 
nursing staff." 
Beyond the amenities aimed at 
creating a comfortable atmosphere, 
the SSU provides a number of sup-
port services. For instance, music 
therapy often is effective for reliev-
ing anxiety; stress management is 
commonly taught to patients who 
need to relax; Pastoral Care or 
Psychiatry services may be needed 
by some patients; and to make the 
patient feel comfortable, phone 
calls to the home are made by a 
nurse before the patient arrives and 
again after he or she goes home. 
Whi le the U n i t greatly benefits 
patients, the Hospital gains f r o m i t 
too. "The admission of one patient 
depends upon the discharge of 
another; i t causes a chain reaction 
throughout the Hospital's i n -
patient units ," says King. "The 
SSU allows us to more easily 
synchronize the f low of patients. 
"For example, some hospitals 
might have a discharge t ime of 11 
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a.m., and that's i t — t h e patient 
either has to leave or the liospital 
is forced to delay another patient's 
admission," she adds. "The U n i t 
gives our patients someplace to go 
and wait , and continue to have the 
nursing care they may need. The 
end result is a more efficient sys-
tem that benefits patients, nurses, 
physicians, and everyone else i n -
volved i n a patient's care." 
The format ion of hospital nurs-
ing units l ike the U H Short Stay 
U n i t is fast becoming a trend at 
many hospitals. W i t h an ever-
changing health-care environ-
ment, hospitals are challenged to 
f i n d ways to deliver the same high 
qual i ty care and he more efficient 
doing i t . The Short Stay U n i t is 
part of the Univers i ty Hospital's 
answer. 
Michael R. Paskavitz 
Time 11:35 a.m. 
Time 3:24 p.m. 
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I have mild hypertension and Fve 
heard there are new ways to treat it. 
N e w guidelines for treating hyperten-
sion (high blood pressure) were issued 
reeently by the Nat ional Heart, Lung 
and Blood Inst i tute . As you may 
know, hypertension is what happens 
w h e n your heart pumps hlood through 
your arteries w i t h a force that is 
greater than necessary. Whi le this can 
damage your arteries and strain your 
circulatory system, hypertension also 
puts you at a greater risk for heart dis-
ease, stroke and kidney failure. 
The new guidelines recommend an 
individual ized "stepped-care" approach 
to treatment, w i t h more options and 
greater f l e x i b i l i t y at each treatment 
step than previously recommended. In 
other words, if the f irst step of treat-
ment doesn't work , the doctor tries the 
next, and so on. 
The first step is a non-drug, self-
help approach: losing weight, l i m i t i n g 
salt and alcohol intake, exercising and 
stopping smoking, among others. If 
these don't work , an i n d i v i d u a l l y 
tailored drug regimen may he 
prescribed. 
Is it true that optimism can in-
fluence one's health and ability to 
recover from disease} 
Several studies have indicated this, hut 
i t is d i f f i cu l t to measure how m u c h a 
hopeful out look—a personality trai t 
l i n k e d to one's self-esteem—actually 
influences health. I n one personality-
and-health study, 99 men were inter-
viewed at age 25 and again at 60, and 
those w h o were pessimistic at age 25 
were less healthy at 60 than were the 
opt imists . 
Some researchers believe that feel-
ings l i k e pessimism and o p t i m i s m may 
he connected to the i m m u n e system's 
ab i l i ty to protect against disease, hut 
few w o u l d say that one's out look w i l l 
decide whether a person gets a cold or 
develops cancer. Science has proven, 
however, that pessimistic personality 
traits, i n combinat ion w i t h other risk 
factors, can contribute to such health 
problems as heart disease and ulcers. 
I n addit ion, i t has heen shown that 
there is a m u c h higher incidence of 
serious illness and death among the 
bereaved. 
I'm only 25 years old and I'm al-
ready showing signs of baldness. 
Would the new drug, Rogaine, 
help me} 
Depending upon your degree of bald-
ness, Rogaine could help. However, al-
though i t has heen shown to effectively 
promote hair g r o w t h i n some men 
whose hair is t h i n n i n g , i t w i l l not help 
those w h o are completely bald. The 
ideal candidate for the drug is a young 
man just beginning to lose his hair he-
cause of hereditary male-pattern bald-
ness. 
The drug, a l i q u i d solution applied 
to the scalp twice a day, usually 
generates i n i t i a l hair g r o w t h i n four to 
six months and m a x i m u m g r o w t h 
w i t h i n a year. But even among the 
r ight candidates, only 20 to 25 percent 
receive the opt imal results,- 25 to 35 
percent have a modest increase and the 
rest see no effect. W h i l e Rogaine could 
w o r k for you, there also are other ways 
to treat baldness, such as hair 
transplants. I n any event, he sure to 
consult your doctor or a dermatologist 
f irst . 
Host my hearing years ago from 
construction noise. Could an 
electronic implant help} 
You prohahly suffered sensorineural 
hearing loss, w h i c h means that sound 
impulses can reach your ear hut not 
your brain hecause of damage to the 
cochlea or perhaps to the auditory 
nerve. By using an electronic i m p l a n t — 
a cochlear implant—impulses can 
bypass the damage i n the cochlea and 
st imulate the auditory nerve directly. 
When this happens, part ial hearing can 
he restored—although often sounding 
distant or scratchy, and i t becomes pos-
If you or any of your family mem-
bers or friends are suffering from 
health problems similar to those 
presented in these questions, and you 
would like to see an appropriate 
physician, or need more information, 
you can call the University Hospital 
at 1-800-842-3648. 
The information in "Health Notes" 
was derived from the University 
Hospital's "Matters of Health," a 
health and wellness column that is 
written in cooperation with the 
physicians and staff of Boston 
University Medical Center. 
sihle to have telephone conversations 
or carry on faee-to-face conversations 
aided hy l i p reading. 
However, a cochlear implant should 
he used only hy those w h o cannot he 
helped hy a conventional hearing aid, 
yet whose auditory nerve is s t i l l intact . 
Conventional hearing aids can usually 
help people w i t h moderate or even 
severe sensorineural hearing loss. 
How are new drugs approved} 
And how can I be assured of their 
safety} 
I t usually takes ahout eight years— 
f r o m conception of the idea to federal 
Food and D r u g A d m i n i s t r a t i o n (FDA) 
approval—for a new drug to become 
available for market ing. Whi le most 
new drugs are developed hy drug com-
panies, ideas for new drugs can 
originate f r o m physicians, researchers, 
pharmacists or drug companies. 
The approval process for new drugs 
involves a very strict protocol . First, 
the drug's effectiveness undergoes 
pre l iminary investigations prior to the 
manufacturer s u b m i t t i n g comprehen-
sive data and a formal application to 
the F D A asking for permission to use 
the drug i n h u m a n subjects (cl inical t r i -
als). Once reviewed and approved for 
c l inical trials hy the FDA, several sites 
(usually hospitals) w i l l he asked to par-
ticipate; each site w i l l undergo its o w n 
internal approval process before begin-
n ing the study. 
C l in ica l trials involve three phases: 
Phase I , s tudying the drug's absorption, 
metabolism, excretion, effects and side 
effects; Phase I I , evaluating the drug's 
effectiveness and short-term effects 
w i t h the disease under study; and Phase 
I I I , randomized t r i a l s — i n v o l v i n g more 
patients—comparing the drug w i t h 
other drugs or a m o c k (placebo) drug. 
A l l c l in ica l t r i a l patients are informed 
ahout the nature of the t r ia l , educated 
ahout its risks and benefits, and are free 
to say yes or no to part ic ipation. 
Some experimental drugs that show 
great promise may he "fast-tracked" 
through a phase. 
If the trials just i fy the continued use 
o i the drug, a N e w D r u g A p p l i c a t i o n 
( N D A ) is submitted for F D A approval 
for market ing. Once available for 
market ing, the drug is closely 
moni tored (Phase IV) hy the F D A to as-
sure that no adverse eiiects were over-
looked i n the c l in ica l trials. The 
manufacturer is responsible for report-
ing on the continued effectiveness o i 
the drug, and must report any adverse 
side eiiects. 
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Meenan Cohen 
^^^^^^ 
• Robert F. Meenan, M.D. , has 
heen appointed as the chief o i the Sec-
t i o n o i Rheumatology at the Univer-
sity Hospital ; he also was named the 
chief o i the A r t h r i t i s Section o i Bos-
t o n Univers i ty School o i Medieine. 
H e also is chief o i Rheumatology at 
Boston C i t y Hospital . Meenan suc-
ceeds Alan S. Cohen, M.D. , as the 
U H chief o i Rheumatology. 
Meenan, a national leader i n 
health-eare research i n rheumatol-
ogy, is a graduate o i the School o i 
Medicine, and received his residency 
t ra in ing at Boston C i t y Hospital and 
his rheumatology tra ining at the 
Univers i ty o i California i n San Fran-
cisco. 
Cohen, w h o has overseen the 
rheumatology program for the past 
27 years, w i l l continue as director o i 
the School o i Medicine's A r t h r i t i s 
Center. 
Ellison Kannel 
• R. Curtis Ellison, M.D. , is the 
new chief o i the Fvans Section o i 
Preventive Medicine/Fpidemiology. 
He succeeds William B. Kannel, 
M.D. , a former director o i the 
renowned Boston Univers i ty-
Framingham Heart Study, w h o w i l l 
continue his association w i t h the Sec-
t i o n . 
El l ison joins U H f r o m his posi-
tions as professor o i medicine and 
pediatrics, director o i research i n the 
D i v i s i o n oi General Medieine and 
director o i the Heart Heal th Program 
at the Univers i ty of Massachusetts 
Medical Center i n Worcester. He is 
internat ional ly k n o w n for high 
qua l i ty epidemiologic research, espe-
c ia l ly i n cardiovascular disease, and 
is a pr inc ipal investigator o i research 
related to the Framingham Heart 
Study. 
m Murray M . 
Freed, M.D. , chief 
o i the U H Depart-
ment o i Rehahilita-
t i o n Medicine, 
was named 
Dist inguished 
C l i n i c i a n hy the American Academy 
oi Physical Medicine and Rehahilita-
t i o n (AAPM&tR), a national organiza-
t i o n o i physicians w h o specialize i n 
rehabi l i ta t ion medieine. 
Freed, w h o directs the Hospital 's 
N e w England Regional Spinal Cord 
In jury Center, is a past-president o i 
the AAPM&tR, the Association o i 
Academic Physiatrists, and the N e w 
England Society o i Physical 
Medicine. He also was cited as 
Physician o i the Year hy the Gover-
nor o i Massachusetts i n 1972. 
• Michael D . 
Higgins is a new 
vice president for 
C l i n i c a l Opera-
tions at the Hospi-
tal . He comes to 
U H f r o m his 
posi t ion as associate administrator at 
the Washington Hospital Center i n 
Washington, D.C. A member o i the 
Amer ican College o i Heal th Care Ex-
ecutives, Higgins received his 
master's degree i n business ad-
m i n i s t r a t i o n f r o m George 
Washington Univers i ty i n 
Washington, D.C. 
Dodge Solomont 
I Dexter A. Dodge and Alan D . 
Solomont were elected members o i 
the Hospital's Board o i Trustees at 
the 134th A n n u a l Meet ing o i the Cor-
poration held i n December. 
Dodge, w h o also is a member o i 
the Board o i Trustees o i Boston 
Univers i ty , is the managing director 
o i Freedom Capital Management Cor-
poration, w h i c h specializes i n 
portfol io management for individuals 
and inst i tut ions . Formerly, he was 
an investment counselor at Loomis, 
Sayles and Company, Inc., and at 
Stone and Webster Securities Cor-
poration. Dodge is a retired brigadier 
general i n the U.S. A i r Force/Mas-
sachusetts A i r Nat iona l Guard. 
Solomont is the president o i ADS 
Management, Inc., a health-care 
management company that develops 
and operates nursing homes and 
ret irement facilities. M r . Solomont, 
a trustee o i the Univers i ty o i Lowel l , 
has heen a special advisor to the 
Dukakis administrat ion on long-term 
care. 
NEWS 
• In December o i 1988, the 
Hospital 's new Magnetic Resonance 
Imaging (MRI) Center was opened. 
W i t h the acquisit ion o i the massive, 
m u l t i - t o n M R I technology, U H now 
has the most sophisticated diagnostic 
device currently available. 
Magnetic resonance imaging 
provides physicians w i t h highly 
detailed diagnostic images w i t h o u t 
the use o i ioniz ing radiation—com-
m o n l y found i n C T scans and other 
radiologic devices. The technology is 
housed i n the Radiology Department 
on the f irst floor o i the A t r i u m 
Pavil ion and is heing used i n col-
laboration w i t h Boston C i t y Hospital . 
I Lavina Cunningham, a Roxhury 
Home Heal th Aide/Homemaker, was 
the f irst i n her profession to receive 
the Univers i ty Hospita l H o m e M edi -
cal Service's coveted C o m m u n i t y Ser-
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vice A w a r d . The award is given hy 
• the H M S each year to an i n d i v i d u a l 
w h o has served the needs of the elder-
l y throughout Greater Boston. 
The H M S is the oldest home medi-
cal program o i its k i n d i n the country, 
having originated i n the late 19th cen-
t u r y w h e n the forerunner o i the 
Univers i ty Hospital , Massachusetts 
Homeopathic Hospital , hegan sending 
its doctors, nurses and medical stu-
dents i n t o the homes o i sick patients. 
• I n conjunct ion w i t h the 
observance o i Dr . M a r t i n Luther King 
Jr. Day i n January, Boston Univers i ty 
Medical Center (BUMC) hosted its 
second annual Black Achievers Day. 
A formal program coupled the celebra-
t i o n o i King's l i fe and accomplish-
ments w i t h the theme o i "350 Years 
o i Black Presence i n Boston." The 
program paid tr ibute to 11 B U M C 
employees w h o were acknowledged 
as Black Achievers for 1989. 
Five o i the honorees—Pauline A l -
l ison, Department oi N u t r i t i o n Ser-
vices; Olga Jones, R.N. , Department 
o i Nurs ing ; Gary M i l l e r , P.A., Home 
Medical Service,- Adr ian Polk, In-
patient Financial Services; and Fran-
cisco Tolent ino, Department o i 
Laboratory Medicine—were f r o m the 
Univers i ty Hospital . 
H A formal r ihhon-cutt ing ceremony 
o i i i c i a l l y opened the Hospital 's new 
"SkyLight" d ining pavi l ion, the brand 
new 10,000-square foot, 325-seat 
din ing fac i l i ty . A p t l y named for its 
modular structure and skyl ight over 
the serving area, "SkyLight" serves as 
the central d in ing area for employees, 
medical-dental staff, ambulatory 
patients and visitors. 
The opening o i the d in ing area 
marks the complet ion o i four and a 
half years o i major new construction 
on the A t r i u m Pavil ion complex. I n 
addit ion to heing twice the size o i the 
former dining area i n the Preston 
Building, "SkyLight" oilers a greater 
selection oi hot and cold foods and 
sandwiches, as w e l l as soups, salads, 
beverages and desserts. 
IN THE NEWS 
Since October o i 1988, the f o l l o w i n g 
Univers i ty Hospita l and/or Boston 
Univers i ty School o i Medicine health 
professionals have appeared i n the 
media as expert sources for 
news stories: 
Sanford H . Auerbach, M.D. , 
Department o i Neurology, was inter-
viewed hy WVBF-radio on the subject 
o i Alzheimer 's Disease Marsha 
Baron-Berg, vice president for C l i n i -
cal Affairs, appeared i n a Voice of the 
Physically Challenged article ahout 
the Blaekstone/ISEC School program 
for the physically disabled Alan 
Bateman, M.D. , Department o i 
Psychiatry, was interviewed hy WBZ-
T V Channel 4's "Live on Four" on 
how and w h y couples decide whether 
to have chi ldren Anna Bissonnette, 
R .N, , Home Medical Service, was the 
subject o i a Boston Globe article 
recognizing her w o r k at the Hospital 
as w e l l as w i t h the homeless and the 
elderly i n Boston's South 
End Desiree Carlson, M.D. , direc-
tor. Blood Bank, appeared i n a Boston 
Globe article ahout the U.S. hlood 
supply David C . Dodson, M.D. , 
Cl in ica l N u t r i t i o n , was interviewed 
ahout the Optiiast diet hy W B Z - T V 
Channel 4's "Evening Magazine," 
"People Are Ta lk ing , " "Prime T i m e , " 
and "Live on 4" Robert G . Feldman, 
M.D. , chief. Department o i Neurol -
ogy, appeared i n an Atlantic Monthly 
article on temporal lobe epilepsy 
(TLE) Robert H . Friedman, M.D. , 
director. Medical In format ion Sys-
tems, was interviewed hy Design 
News ahout his ta lk ing computer sys-
tem (TLC) Barbara A. Gilchrcst, 
M.D. , chief. Department o i Dermatol-
ogy, appeared i n a W N E V - T V Chan-
nel 7 news segment and i n Boston 
Globe, Wall Street fournal and Buf-
falo News articles ahout the positive 
eiiects o i Retin-A i n preventing skin 
cancer Irwin Goldstein, M.D. , 
Department o i Urology, was featured 
i n the syndicated CBS special "Inside 
the Sexes," on ABC's "Good M o r n i n g 
America" and on WBZ-TV's "Evening 
Magazine," and was interviewed hy 
Time magazine, U.S. News and 
World Report, the Boston Globe and 
the Daily Free Press for his w o r k 
w i t h new surgical treatments for i m -
potence Michael Holick, Ph.D., 
M.D. , head. Metabolic Bone Disease 
Cl in ic , appeared on the W N E V - T V 
Channel 7 news for his w o r k w i t h 
psoriasis treatments, and also was i n -
terviewed hy W B Z - T V Channel 4 and 
hy the Boston Herald ahout the posi-
t ive eiiects o i sunlight therapy during 
the winter i n people w i t h v i t a m i n D 
deficiency I n the same Boston 
Herald article, Amal Kurban, M.D. , 
Department o i Dermatology, talked 
ahout the dermatologic implicat ions 
o i not having sufficient moisture 
during the winter Karen K. Kirby, 
R.N. , senior vice president for Nurs-
ing, was interviewed ahout solutions 
for the nursing shortage i n articles for 
the Medical Tribune, Woburn Daily 
Times &) Chronicle, Kent County 
Daily Times (R.I.), Manchester Sun-
day News (N.H.) , and the Williman-
tic Chronicle (Conn.) Howard Koh, 
M.D. , Department o i Dermatology 
and Section o i Medical Oncology, ap-
peared i n a W B Z - T V Channel 4 seg-
ment and was interviewed hy the Bos-
ton Herald and Daily Free Press con-
cerning his w o r k w i t h photopheresis; 
he also was profi led i n the Reading 
Chronicle Robert E. Leach, M.D. , 
chief. Department o i Orthopedic 
Surgery, was interviewed hy the 
Daily Free Press for an article on 
steroids and athletes David C . 
Leiman, M.D. , Department o i 
Psychiatry, was interviewed on WEEI-
radio ahout holiday depres-
sion Lawrence J. Markson, M.D. , 
Section o i Geriatrics, was i n a WCVB-
T V Channel 5 news report ahout the 
issue o i durable power o i attor-
ney Ronald P. McCaffrey, M.D. , 
chief. Section o i Medical Oncology, 
was i n a Woburn Daily Times &) 
Chronicle article on a new treatment 
for chronic lymphocyt ic 
leukemia Thomas J. Ryan, M.D. , 
chief. Section o i Cardiology, appeared 
on W N E V - T V Channel 7's "Boston 
C o m m o n " and was quoted i n 
Reader's Digest, Boston Globe and 
Press &) Sun Bulletin (Binghamton, 
NY) articles on balloon angioplasty; 
he also appeared on the "Boston Com-
m o n " N e w Year's program to ta lk 
ahout medicine i n 1988 and what to 
expect for 1989 David J. Salant, 
M.D. , chief. Section o i Renal 
Medieine, was interviewed hy the 
Holyoke Transcript-Telegram for an 
article on renal failure. 
Correction: In the last issue of 
Progress, Dr. Thomas F. Freddo, 
Department of Ophthalmology, was 
erroneously listed as an M.D. His 
actual degree standing is an O.D., a 
doctor of optometry. 
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Now there's help for 
grown-up children who are 
concerned about aging parents 
The Geriatric Evaluation Center provides a 
comprehensive assessment of individuals who 
are 65 years or older. Our assessment team is 
comprised of board-certified geriatricians, a 
geriatrics nurse-specialist and a licensed, 
masters-prepared social worker. 
Our program assists primary-care physi-
cians and families with the medical, psychologi-
cal, social and financial problems that hinder 
the older adult's daily functioning and 
independence. 
Evaluations of older adults are recom-
mended for such difficulties as: 
• multiple medical illnesses 
• new onset of problems with memory 
• Alzheimer's disease or other dementing Ulness 
• decisions regarding nursing home placement 
The Geriatric Evaluation Center offers 
access to a distinguished groupjif physicians, 
social workers, nurses a^ d^ spepial programs. 
The Hospital's nationally recognized Home 
Medical Service provides close linkage with a 
host of community services throughout the 
Greater Boston area. We are committed to 
respecting the referring physician's relation-
ship with patients who may be referred to the 
Geriatric Evaluation Center and to providing 
timely and thorough information. Medicare and 
other third-party payors cover most of the costs 
associated with an evaluation. 
All patient visits to the Geriatric Evalua-
tion Center, as well as evaluative testing, take 
place in the Hospital's Doctors Office Building. 
Convenient indoor parking is available in the 
Doctors Building garage. 
For more information about how the Geria-
tric Evaluation Center can assist you in manag-
ing the health of an aging parent and to request 
our informational brochure, please hll in the 
form below or call: 1-800-842-3648 
Please send me a copy of your Geriatric 
Evaluation Center brochure. 
Name 
Address. 
City 
State. .Zip. 
T h e 
U n i v e r s i t y 
H o s p i t a l 
Geriatric Evaluation Center, 720 Harrison Avenue, 5th floor, Boston, MA 02118 617/638-8398 
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